A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (REVEAL-ND NPM1): Trial in progress

Abstract

Author

Stein EM, et al.

Congress

European Hematology Association Annual Congress 2026

Stockholm, Sweden | June 11 – 14, 2026